Aktieanalys

Enzymatica: MDR certification - Redeye

{newsItem.title}

Redeye Publicerad: 11 Mar 2024 13:55

Redeye is positive about Enzymatica’s new MDR certification for its mouth spray ColdZyme. The certification (class III) validates the company’s scientific data and product claims in the EU, and it is essential from a commercial perspective. We reiterate our base case of SEK6.

Länk till analysen i sin helhet: https://www.redeye.se/research/989769/enzymatica-mdr-certification?utm_source=finwire&utm_medium=RSS

Nyheter om Enzymatica

Läses av andra just nu

Om aktien Enzymatica

Senaste nytt